Abstract
OBJECTIVES: This article aims to evaluate the feasibility and acceptability of intensive assessment of symptoms in RA patients starting a new biologic treatment. METHODS: Participant symptoms and experiences were collected six times a day for 14 days and once a day for 16 days in a single cohort. Wearable devices were also given to participants to track sleep and physical activity. Qualitative interviews were conducted to provide feedback regarding the acceptability of methods. Recruitment and completion rates were used to test for feasibility. The mean and variability of data for each day were calculated to reflect on data quality. Qualitative interview data were analysed by deductive thematic analysis. RESULTS: Of the 110 patients approached, 27 (15.5%) could not be contacted and 12 (14.5%) were excluded due to meeting exclusion criteria. Of 71 contactable and eligible participants, 31 (43.7%) joined the study. The survey completion rate was 74.6% (1943/2604) for the first 14 days, ranging from 10.7 to 100%. Completion rates for days 15-30 ranged from 60 to 83%. Mean levels of severity of symptoms (pain, fatigue, joint stiffness) showed a decrease after treatment, as expected. Qualitative interviews demonstrated that participants reported a positive experience that was not overly burdensome. Surveys were described as quick and easy to complete, but repetitive for some participants. DISCUSSION: Recruitment and completion rates were acceptable and comparable to similar studies in the field. Qualitative analysis showed largely positive reviews from participants with feedback mainly focusing on survey timings.